Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Liabilities Leasing Arrangements

Deferred Tax Liabilities Leasing Arrangements at other companies

Piper Sandler logo
Piper SandlerPIPR
$15.28M-1.8%
WSFS Financial logo
WSFS FinancialWSFS
$21.61M-21.5%
OGS
ONE GASOGS
$2.94M-23.9%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$4.22M+2,983%
ESAB logo
ESABESAB
$28.42M+28.7%
Trupanion logo
TrupanionTRUP
$3.3M

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.67B+52.9%
Enterprise value$2.56B+48.4%
P/S4.4×-1.5×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesLeasingArrangements.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026.

Filed
Feb 23, 2026, 4:11 PM EST
Fiscal year
FY2025
Accession
0001819790-26-000019
Line itemYear Ended December 31, 2025Year Ended December 31, 2024
Total deferred tax assets before valuation allowance112,67388,397
(Less): Valuation allowance(107,935)(88,043)
Total deferred tax assets$4,738$354
Deferred tax liabilities, net:
Operating lease right-of-use assets(4,224)(137)
Fixed assets(186)(217)
Prepaid expenses(328)
Net deferred tax asset

Item 8. Financial Statements and Supplementary Data

FAQ

What is Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities leasing arrangements?
Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax liabilities leasing arrangements of $4.22M in Q4 2025.
How has Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities leasing arrangements changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities leasing arrangements increased by 2983.2% year-over-year, from $137K to $4.22M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities leasing arrangements?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities leasing arrangements has grown at a 95.5% compound annual growth rate (CAGR), from $148K to $4.22M.
What does deferred tax liabilities leasing arrangements mean?
Deferred Tax Liabilities Leasing Arrangements as reported by Tarsus Pharmaceuticals, Inc. Common Stock.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities leasing arrangements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude